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Clinical ef®cacy of cultured skin substitutes may be
increased if their carbohydrate metabolism is opti-
mized by understanding whether endogenous insu-
lin-like growth factor I can substitute for exogenous
insulin. Cultured skin substitutes were prepared and
incubated at the air±liquid interface for 4 wk in
media containing 0.5 or 5 mg per ml insulin, 10 or
50 ng per ml insulin-like growth factor I, or 0 insulin
and 0 insulin-like growth factor I (negative control).
In situ hybridization showed that the epidermal and
dermal cultured skin substitute components express
insulin-like growth factor I mRNA throughout the
28 d interval. Immunohistochemistry con®rmed the
expression of insulin-like growth factor I protein by
the human keratinocytes and ®broblasts in cultured
skin substitutes. Insulin-like growth factor I at 10 or
30 ng per ml could partially replace insulin in a
clonal assay of keratinocyte growth. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assays showed signi®cantly higher val-
ues in cultured skin substitutes incubated with insulin
at incubation days 14 and 28 compared to negative
control or the 10 ng per ml insulin-like growth fac-
tor I condition. Cultured skin substitutes incubated
in 50 ng per ml insulin-like growth factor I had
MTT values similar to the insulin-treated cultured
skin substitutes at day 14, but were signi®cantly
lower by day 28. Light microscopy agreed with
MTT data showing that cultured skin substitutes
grown with insulin media had multiple layers of
nucleated keratinocytes and stratum corneum at days
14 and 28. The negative control and 10 ng per ml
insulin-like growth factor I exhibited poor cultured
skin substitute epidermal morphology throughout
the experiment. In contrast, the cultured skin substi-
tutes in 50 ng per ml insulin-like growth factor I
were similar to the insulin-treated cultured skin sub-
stitutes at day 14, but by day 28 had deteriorated to
resemble the negative control. Bromodeoxyuridine
incorporation at day 28 was signi®cantly higher for 5
mg per ml insulin cultured skin substitutes versus all
other treatment groups. These data suggest that
medium containing 5 mg per ml insulin supports
greater physiologic stability in cultured skin sub-
stitutes over time, and that expression of insulin-
like growth factor I by keratinocytes and ®broblasts
in cultured skin substitutes is not suf®cient to fully
replace the requirement for exogenous insulin in vitro.
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C
ultured skin substitutes (CSS) have become adjunc-
tive therapies for treatment and healing of full-
thickness skin wounds (Boyce, 1996). Epidermal
barrier is the de®nitive property of wound closure,
and consists of a variety of lipids that are synthesized
in keratinocytes from two-carbon subunits produced by catabolism
of carbohydrates (Elias, 1983; Ponec et al, 1997). Therefore,
formation of epidermal barrier depends on carbohydrate metabo-
lism of keratinocytes. Carbohydrate uptake is regulated primarily by
extracellular insulin, which is delivered from the plasma in vivo and
is a universal requirement for serum-free culture of nontransformed
human cells (Ham and McKeehan, 1979). It is also known that
insulin-like growth factor I (IGF-I) supports proliferation of
nontransformed cells in culture, that it can bind to the insulin
receptor (LeRoith et al, 1994), and that it is mitogenic for both
keratinocytes and ®broblasts in culture (Conover et al, 1985;
Nickoloff et al, 1988; Ristow and Messmer, 1988; Barreca et al,
1992; Kratz et al, 1992). It is not clear whether IGF-I can substitute
for insulin in the proliferation and differentiation of keratinocytes
and ®broblasts incubated to generate CSS, however, nor whether
autocrine and paracrine release of IGF-I from cells in CSS can
reduce or eliminate the requirement for exogenous insulin.
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IGF-I is a 70 amino acid peptide that has approximately 50%
structural homology to proinsulin (Daughaday and Rotwein,
1989). Generally, intermediary metabolism is regulated by insulin
via the insulin receptors on liver, fat, and muscle cells. In contrast,
IGF-I is ascribed the function of growth by acting through the type
I IGF receptors found on most cells (LeRoith et al, 1994). IGF-I is
found in human serum associated with one of its binding proteins
and it is responsible for the somatotropic effects of growth hormone
(Clark, 1997). Insulin and IGF-I have structurally homologous high
af®nity receptors in most tissues including the human epidermis and
dermis (Nickoloff et al, 1988; Krane et al, 1991; Neely et al, 1991;
Tavakkol et al, 1992; LeRoith et al, 1994). IGF-I and insulin can
bind to each other's respective receptor, but with lower af®nity
(Neely et al, 1991). High doses of insulin bind the type I IGF
receptor and can mimic the activity of IGF-I in epidermal cell
culture medium (Ristow and Messmer, 1988; Aaronson et al, 1990;
Neely et al, 1991). Cultured human ®broblasts and melanocytes,
but not human keratinocytes, have been reported to produce IGF-I
(Tavakkol et al, 1992, 1999), although upon ultraviolet B
irradiation IGF-I immunoreactivity was observed in the mouse
epidermis (Hansson et al, 1988) and the healing epithelial edge of
full-thickness cutaneous wounds expressed IGF-1 protein and
mRNA in mice (Brown et al, 1997). In addition, the differentiated
human keratinocytes of the stratum granulosum and dermal
®broblasts were positive for IGF-I by in situ hybridization
(Rudman et al, 1997), and by immunohistochemistry in all layers
of uninjured human epidermis (Blakytny et al, 2000).
The function of IGF-I has been investigated in wound healing.
IGF-I mRNA levels were elevated in rat wounds with no change
in IGF-I receptor expression (Gartner et al, 1992; Steenfos and
Jansson, 1992). Wound repair was signi®cantly accelerated when
mouse wounds were treated with a combination of IGF-I and IGF
binding protein I (Tsuboi et al, 1995). Wounds created on human
skin cultured in vitro re-epithelialized at a greater rate in the
presence of IGF-I (Kratz et al, 1994). Lynch et al (1989) found that a
combination of platelet-derived growth factor 2 and IGF-I
stimulated the epidermal and dermal development in porcine
partial-thickness wounds. Recombinant human growth hormone
when delivered by subcutaneous injection resulted in improved
healing times of graft donor sites for burn wounds presumably by
induction of IGF-I (Herndon et al, 1995). Burn patients with large
burns had lower IGF-I serum levels that correlated with the level of
serum albumin (Moller et al, 1991). This reduced IGF-I concen-
tration may be responsible in part for the reduced healing observed
in these patients. In the postburn hypertrophic scar, elevated levels
of IGF-I and type I collagen were measured (Ghahary et al, 1995).
In a subsequent study, ®broblasts derived from the hypertrophic
scars synthesized less collagenase mRNA when treated with IGF-I,
but increased type I collagen production in vitro (Ghahary et al,
1996). Thus, IGF-I may positively in¯uence wound healing, but
IGF-I overexpression may have deleterious consequences.
Previous studies from this laboratory have demonstrated closure
of large burns and chronic wounds with CSS (Boyce et al, 1995a, b,
1999; Harriger et al, 1995). CSS are composed of autologous
human keratinocytes and ®broblasts inoculated onto a collagen-
glycosaminoglycan (GAG) biopolymer substrate (Boyce and
Hansbrough, 1988; Boyce, 1998). CSS have been shown to
generate epidermal barrier in vitro that contributes to more rapid
wound closure (Boyce et al, 1996; Supp et al, 1999). Medium
containing insulin supports the formation of epidermal barrier with
simultaneous maintenance of proliferation of keratinocytes and
®broblasts (Boyce et al, 1997). Preliminary studies suggested that
endogenous IGF-I in the absence of insulin may support
keratinocyte metabolism and limited differentiation (Swope et al,
1997a, b). The studies reported here were designed to investigate
whether endogenous or exogenous IGF-I can support the prolif-
eration and differentiation of keratinocytes and ®broblasts in CSS,
and whether IGF-I is expressed in the epidermal and/or dermal
compartments of the skin substitute.
MATERIALS AND METHODS
Cell culture and clonal growth assay Human keratinocytes and
®broblasts were isolated simultaneously from surgical discard tissue using
selective growth media and cryopreserved at passage 1 for these
experiments (Boyce and Ham, 1983; 1985). For the clonal growth assays,
human keratinocytes were inoculated at 25 cells per cm2 into the test
conditions (n = 4) and cultured at 37°C and 5% CO2. The basal
medium consisted of modi®ed MCDB 153 (Pittelkow and Scott, 1986)
supplemented with 0. 5 mg per ml hydrocortisone and penicillin-
streptomycin-Fungizone. Human recombinant IGF-I (Peprotech, Rocky
Hill, NJ) was tested at 1±30 ng per ml in the presence and absence of
1 ng per ml human recombinant epidermal growth factor (EGF) (Gibco,
Rockville, MD). The media were changed four times during the 12 d
culture period and the cell colonies were stained at the end of the
experiment with 0.1% crystal violet prepared with 2% glutaraldehyde in
0. 05 M sodium cacodylate buffer. After 10 min of staining, excess
crystal violet stain was removed from the dishes by rinsing with tap
water and the dishes were air dried. The crystal violet was released with
1% sodium dodecyl sulfate and the absorbance at 590 nm was measured
with a microplate reader (Model 7520 Cambridge Technologies,
Watertown, MA). The optical density correlates directly with cell
number.
CSS preparation The CSS (n = 3 per condition) were prepared by
sequential inoculation with human ®broblasts (0.5 3 106 per cm2) and
human keratinocytes (1.0 3 106 per cm2) onto acellular collagen-GAG
biopolymer substrates as previously described (Boyce et al, 1991) with
the following modi®cations. The CSS medium consisted of Dulbecco's
modi®ed Eagle's medium (1.8 mM Ca2+) supplemented as reported by
Chen with modi®cations (Chen et al, 1995). Insulin (0, 0.5, or 5 mg per
ml) or IGF-I (0, 10, or 50 ng per ml) was added beginning on day 0
(day of human keratinocyte inoculation onto the collagen substrate). The
negative control was represented by CSS cultured in medium with 0 mg
per ml insulin + 0 ng per ml IGF-1. On day 3 after human keratinocyte
inoculation, the CSS were lifted and maintained at the air±liquid
interface in saturated relative humidity at 37°C and 5% CO2 (Boyce and
Williams, 1993). Test media were replaced daily for 4 wk. Samples were
taken weekly for histologies, biweekly for the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, and at the 4 wk time
point for 5-bromo-2¢-deoxyuridine (BrdU) incorporation. For light
microscopy CSS biopsies were ®xed in 2% paraformaldehyde/2%
glutaraldehyde in 0.1 M sodium cacodylate buffer, embedded in glycol-
methacrylate, sectioned, and stained with Toluidine Blue.
MTT assay On days 14 and 28, 6 mm punch biopsies (n = 3 CSS
per condition; 12±18 punches per condition) were taken from each CSS
condition and incubated for 3 h at 37°C with 0.5 mg per ml MTT
(Sigma, St. Louis, MO). The mitochondria of viable cells cleave the
tetrazolium salt MTT to formazan (Mosmann, 1983). The MTT
formazan reaction product was released by incubating the biopsies in 2-
methoxyethanol for 3 h on a rotating platform. The optical density of
the MTT formazan product was read at 590 nm on a microplate reader.
BrdU incorporation One square centimeter CSS biopsies were
incubated for 22 h with 65 mM BrdU (Roche Molecular Biochemicals,
Indianapolis, IN) in a lifted format on day 28. The BrdU-labeled tissue
was ®xed in 10% buffered neutral formalin and processed for paraf®n
embedding. The tissue sections were deparaf®nized and rehydrated in
graded alcohols. Three 0.01 M phosphate-buffered saline washes were
performed between the labeling steps outlined below and all solutions
were prepared in the same buffer. The CSS sections were partially
digested with 0.025% trypsin for 20 min at 37°C followed by 2% bovine
serum albumin to inactivate the trypsin. The cellular DNA was
denatured with 1.5 N HCl for 15 min at 37°C and then neutralized
with 0.1 M sodium tetraborate. Following a blocking step, the sections
were incubated with murine anti-BrdU ¯uorescein isothiocyanate
(FITC) (Becton Dickinson, San Jose, CA) at 4°C overnight. Rabbit
antipancytokeratin (Zymed Laboratories, South San Francisco, CA) was
added to the CSS sections for 90 min and then followed with goat
antirabbit IgG-Texas Red antibody (Southern Biotechnology Associates,
Birmingham, AL). The slides were coverslipped with Fluoromount G
(Southern Biotechnology Associates). The BrdU-positive human
keratinocytes were determined by counting the number of BrdU-FITC
positive/pancytokeratin-Texas Red positive cells per ®eld (®eld length
550 mm). Four to six unique sections were counted per CSS (n = 3 CSS
per condition) at the day 28 time point.
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Immunohistochemistry CSS biopsies 0.25 cm2 (n = 6 CSS) were
processed for cryostat sectioning by freezing in M-1 embedding matrix
(Shandon-Lipshaw, Pittsburgh, PA). The 15 mm CSS sections were ®xed
in acetone and rehydrated in 0.05 M Tris-buffered saline, pH 7.5.
Multiple washes with 0.05 M Tris-buffered saline/0.05% Tween-20 took
place between each step in humidi®ed chambers at room temperature.
Following a blocking step, the sections were incubated in 10 mg per ml
murine antihuman IGF-I (Serotec, Raleigh, NC) or 10 mg per ml mouse
IgG negative control (Serotec) for 30 min. The biotinylated secondary
antibody (Vectastain Universal Elite ABC kit; Vector Laboratories;
Burlingame, CA) was pipetted onto the CSS sections. Endogenous
peroxidase activity was inhibited with a 0.3% hydrogen peroxide
incubation step. The slides were incubated with the Vectastain Elite
ABC reagent, which is a mixture of avidin and biotinylated horseradish
peroxidase, for 30 min. Biotinyl tyramide (Renaissance Tyramide Signal
Ampli®cation-Indirect kit; NEN Life Science Products, Boston, MA)
was utilized to enhance the IGF-I signal. The biotinyl tyramide
ampli®cation system employs horseradish peroxidase to catalyze biotin-
labeled tyramide deposition at the site of the horseradish peroxidase
enzyme. Streptavidin-horseradish peroxidase was incubated with the
tyramide-labeled sections followed by diaminobenzidine
tetrahydrochloride (Vector Laboratories), the peroxidase substrate. The
tissue sections were dehydrated, cleared, and mounted with permount.
In situ Hybridization CSS biopsies 0.25 cm2 (n = 3 CSS) were ®xed
in 4% paraformaldehyde for 20 h at room temperature and processed for
paraf®n embedding. To reduce the ribonuclease contamination, all
solutions were prepared with diethyl-pyrocarbonate-treated, autoclaved
water and multiple washes were performed between each step. Tissue
sections were deparaf®nized in xylene and rehydrated in graded alcohols
and 0.01 M phosphate-buffered saline. Post®xation was carried out with
4% paraformaldehyde and the sections were treated sequentially with
10 mg per ml glycine, 0.2% tritonX-100, and 3 mg per ml proteinase K
for 60 min at 37°C and then post®xed with 4% paraformaldehyde. The
slides were washed with 0.1 M triethanolamine and 0.1 M
triethanolamine/0.25% acetic anhydride to acetylate the tissue. CSS
sections were dehydrated in graded alcohols and air dried for 1 h.
Prehybridization and hybridization occurred in the following solution:
4 3 saline±sodium citrate buffer (SSC), 0.3% sodium pyrophosphate,
0.6% polyvinyl pyrrolidone (mw 40,000), 0.6% ®coll (mw 400,000),
5 mg per ml acetylated bovine serum albumin, and 0.1 mg per ml
salmon sperm DNA. The CSS tissue sections were prehybridized at
55°C in humidi®ed chambers for 90 min. The hybridization solution
consisted of 1 ng per ml digoxigenin (DIG)-labeled IGF-I antisense or
sense riboprobes that had been denatured for 5 min at 80°C and
incubated overnight with the CSS sections at 55°C. The riboprobes
were produced by linearization of a cloned IGF-I plasmid (ATCC,
Rockville, MD) and DIG transcription labeling using a DIG RNA
Labeling kit (Roche Molecular Biochemicals) (Brown et al, 1997).
Posthybridization included multiple wash steps with 0.5 3 SSC/
1 mM ethylenediamine tetraacetic acid (EDTA) at 55°C, 50% forma-
mide/0.15% sodium chloride/5 mM Tris-HCl/0.5 mM EDTA, 0.5 3
SSC, and 0.2 3 SSC at 55°C. The tissue sections were incubated with
20 mg per ml RNAse A and 10 units per ml RNAse T1 for 30 min at
37°C. Blocking with 1% serum (Roche Molecular Biochemicals) took
place at room temperature for 90 min. The CSS sections were incubated
overnight at 4°C with an alkaline phosphatase conjugated anti-DIG
antibody (Roche Molecular Biochemicals) diluted at 1:750 in blocking
buffer. On the following day, the sections were exposed to the alkaline
phosphatase substrate, BM purple (Roche Molecular Biochemicals), in
the dark for 1±2 h at room temperature and preserved with Crystal
Mount (Biomeda, Foster City, CA). Speci®city of the in situ hybridiza-
tion reaction was con®rmed by the absence of hybridization of the anti-
sense probe following pretreatment of CSS sections with RNAse A
(200 mg per ml, 2.5 h, 37°C).
Figure 1. Cultured skin substitues (CSS) express mRNA and protein for insulin-like growth factor-I (IGF-I) after 21 d incubation in
vitro. (A) In situ hybridization of IGF-I anti-sense riboprobe to CSS showing strong labeling in nucleated keratinocytes of the epidermal component,
and uniform staining in ®broblasts in the dermal component. (B)Immunohistochemical staining with anti-IGF-I monoclonal antibodies shows positive
staining for human IGF-I protein in both the epidermal and the dermal components of CSS. (C ) In situ hybridization of IGF-I sense riboprobe to CSS
showing no labeling in CSS. (D) No staining is observed with murine IgG as the primary antibodies. Scale = 0.128 mm.
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Surface electrical capacitance (SEC) SEC represents a measure of
skin surface hydration, which is inversely proportional to the electrical
impedance (Boyce et al, 1996; Supp et al, 1999). The NOVA Dermal
Phase Meter (DPM 9003; NOVA Technology, Gloucester, MA), which
is based on electrical impedance, was used to measure the SEC on the
CSS in vitro. The application of a current between two electrodes at the
skin surface enables the NOVA meter to detect an electrical phase shift
over time. The magnitude of the phase shift increases as water
accumulates at the site of the capacitance probe, with corresponding
increase in the SEC values. Therefore, CSS with intact barrier yield low
SEC values and CSS with poor barriers result in high SEC readings.
Ten serial readings at 1 s intervals were recorded from each CSS on
culture days 7, 10, 14, 17, 21, 24, and 28. Six SEC measurements were
taken on each of three CSS per condition at each time point (18 SEC
values per treatment group). The SEC data are expressed in picofarads as
mean 6 SEM.
Statistical analysis The data represent the mean 6 SEM for each
condition. The human keratinocyte clonal growth experiments, MTT
assay, and BrdU incorporation data were analyzed by a one-way
ANOVA. The method used for multiple comparisons was Student±
Newman±Keuls and signi®cance was established at the 95% con®dence
level (p < 0.05).
RESULTS
IGF-I expression by CSS CSS were incubated in vitro for 28 d
including 25 d at the air±liquid interface. Paraf®n sections were
prepared for in situ hybridization at weekly intervals. The collagen-
GAG substrate contains numerous ®broblasts uniformly spaced
throughout the collagen sponge, and a well organized epithelium
and stratum corneum (Fig 1). The IGF-I antisense riboprobe
Figure 3. Epidermal morphology of CSS depends on insulin after 28 d incubation in vitro. Insulin, but not IGF-I, supports full strati®cation
and differentiation of the epidermal component of CSS, including an analog of the stratum corneum. (A) Insulin at 5 mg per ml, (B) insulin at 0.5 mg
per ml, (C ) IGF-I at 50 ng per ml generated a thin epithelium with fewer layers of nucleated or corni®ed keratinocytes. (D) Incubation with 0 mg per
ml insulin + 0 ng per ml IGF-I also generated a very thin epithelium with few nucleated layers, similar to (C ). Scale = 0.128 mm.
Figure 2. Growth of cultured human keratinocytes responds to
IGF-I as a function of concentration in the presence of epidermal
growth factor (EGF). The positive control condition of insulin (5 mg
per ml) and EGF (1 ng per ml) ( - - - - ) stimulates maximum growth
(1.1 OD590 units) of keratinocytes in the clonal growth assay.
Substitution of IGF-I at 10 or 30 ng per ml (d) with EGF stimulates
statistically signi®cant increase of growth compared with IGF-I without
EGF (s), but remains signi®cantly less than insulin and EGF. (*p<0.05
versus all other conditions).
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hybridized strongly with the epidermal cells and ®broblasts of the
CSS (Fig 1A). The DIG-labeled sense probe served as the negative
control as shown in Fig 1C with minimal background evident. The
IGF-I message was expressed at weeks 1 through 4 of in vitro culture.
The ability of the CSS to synthesize IGF-I protein in vitro was
con®rmed using immunohistochemical techniques. The epidermis
and dermis of the CSS stained positively for the presence of IGF-I
at all time points (Fig 1B). No staining was observed after reaction
of CSS with nonspeci®c murine IgG as the primary antibody
(Fig 1D). The intensity of the diaminobenzidine staining appeared
greatest at the day 21 time point, indicating a peak in IGF-I
synthesis in CSS maturation.
IGF-I stimulation of keratinocyte proliferation Human
keratinocyte proliferation was stimulated signi®cantly by IGF-I at 10
or 30 ng per ml plus 1 ng per ml EGF (0.48 6 0.05 or 0.61 6 0.06
OD590, respectively) compared to IGF-I at 10 or 30 ng per ml
without EGF (0.27 6 0.01 or 0.29 6 0.09 OD590, respectively)
(Fig 2). At the concentrations tested, IGF-I did not substitute fully
for insulin at 5 mg per ml plus 1 ng per ml EGF. Keratinocyte
proliferation was not stimulated by either insulin (5 mg per ml) in the
absence of EGF (data not shown), or IGF-1 (1±30 ng per ml).
IGF-I substitution for insulin in growth medium of
CSS In Fig 3A, light microscopy of CSS at day 28 shows that
the CSS grown in 5 mg per ml insulin had abundant epithelial cell
layers and stratum corneum. Incubation in 0.5 mg per ml insulin
generates CSS with variable morphology with fewer layers of
nucleated and corni®ed keratinocytes (Fig 3B). Culture medium
with 50 ng per ml IGF-I resulted in poor CSS morphology (Fig 3C)
with few layers of nucleated human keratinocytes and minimal
stratum corneum. At day 28, there was no morphologic difference
between the 50 ng per ml IGF-I CSS and the 0 mg per ml insulin
+ 0 ng per ml IGF-I negative control (Fig 3D). At the day 14 time
point, the 10 ng per ml IGF-I and negative control conditions had a
poorer morphology than the other conditions. The 50 ng per ml
IGF-I condition at day 14 more closely resembled the insulin-
containing groups histologically (data not shown), but deteriorated
by day 28.
Culture conditions with either 0.5 or 5 mg per ml insulin
(1.05 6 0.03 or 1.05 6 0.08 OD590, respectively), or 50 ng per ml
IGF-I (0.92 6 0.04 OD590), generated signi®cantly greater MTT
formazan versus the other culture conditions at day 14 (Fig 4). By
day 28 of in vitro culture, the MTT formazan values from CSS
grown in the negative control medium (0.67 6 0.03 OD590) and
IGF-I at 10 or 50 ng per ml (0.66 6 0.03 or 0.74 6 0.07 OD590,
respectively) were signi®cantly lower than those from CSS cultured
with 0.5 or 5.0 mg per ml insulin (1.21 6 0.08 or 0.98 6 0.10
OD590, respectively). The MTT data from the 50 ng per ml IGF-I
condition were not statistically different at day 14 from the insulin-
treated CSS, but had signi®cantly lower MTT values by day 28,
suggesting cellular degeneration in the CSS.
BrdU labeling of epidermal cells Double labeling for DNA
synthesis and intracellular keratin allowed for the identi®cation of
BrdU-positive keratinocytes in the CSS at day 28 (Fig 5A). The
BrdU incorporation was almost exclusively con®ned to basal
human keratinocytes in the epidermal component and a small
number of ®broblasts in the dermal compartment of the CSS. At
day 28 of in vitro culture, BrdU labeled a signi®cantly greater
Figure 4. Insulin stimulates greater mitochondrial metabolism
than IGF-I after 14 or 28 d of incubation of CSS. At 14 d of
incubation, insulin at 5 mg per ml or 0.5 mg per ml, or IGF-I at 50 ng
per ml stimulated signi®cantly greater MTT conversion than 0 mg per ml
insulin plus 0 ng per ml IGF-I, or 10 ng per ml IGF-I (*p<0.05). At
28 d of incubation, 5 mg per ml or 0.5 mg per ml insulin stimulated
signi®cantly greater MTT conversion than IGF-I at 10 ng per ml or
50 ng per ml, or 0 mg per ml insulin and 0 ng per ml IGF-I (*p<0.05).
Figure 5. Insulin stimulates greater DNA synthesis than IGF-I at
28 d of incubation of CSS. (A) BrdU labeled keratinocytes and
®broblasts occur frequently in CSS incubation in insulin.
Scale = 0.128 mm (B) Insulin at 5 mg per ml stimulates signi®cantly
greater incorporation of BrdU than other conditions tested (*p<0.05).
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number of basal keratinocytes incubated with 5 mg per ml insulin
(7.51 6 2.15 human keratinocytes per ®eld) than all other groups
(Fig 5B), including the 0.5 mg per ml insulin condition
(1.14 6 1.10 human keratinocytes per ®eld).
Epidermal barrier in CSS incubated with IGF-I In Fig 6,
SEC was the same for all conditions at the day 7 and day 10 time
points (data not shown). The SEC values were statistically higher
for the negative control lacking insulin and IGF-I at day 14, 17, 21,
and 28, indicating poor barrier development. SEC values for all
other treatment groups were not statistically different from each
other, nor from values for native human skin of normal volunteers.
DISCUSSION
IGF-I is an important autocrine/paracrine factor for the growth and
function of both keratinocytes and ®broblasts in the skin (Nickoloff
et al, 1988; Barreca et al, 1992; Kratz et al, 1992). These studies were
designed to elucidate the physiologic role of IGF-I in the growth
and maturation of CSS. Using immunohistochemistry and in situ
hybridization, IGF-I protein and mRNA were detected in the CSS
during the 4 wk culture period (Fig 1). Several studies have noted
the presence of IGF-I in the epidermis of normal human skin
(Rudman et al, 1997; Tavakkol et al, 1999; Blakytny et al, 2000),
and injured murine epidermis exposed to ultraviolet B irradiation
was positive for IGF-I (Hansson et al, 1988). Also, IGF-I was
present in the regenerating epithelial wound edge of mice (Brown
et al, 1997). The CSS represents rapidly proliferating human
keratinocytes and human ®broblasts similar to a healing wound and
IGF-I was identi®ed throughout the epidermal and dermal
components of the CSS.
IGF-I alone did not support human keratinocyte clonal growth
in the absence of EGF (Fig 2). These results were consistent with
the poor stimulation of human keratinocyte growth provided by
insulin-containing medium de®cient in EGF (data not shown). If
EGF was added to the human keratinocyte culture medium, insulin
(5 mg per ml) stimulated the keratinocyte growth to a signi®cantly
greater degree than IGF-I (1±30 ng per ml). The increased growth
of human keratinocytes in the presence of insulin together with
EGF in the culture medium suggests that optimal human
keratinocyte responses were mediated through receptors for both
mitogens. Because only insulin promotes glucose transport, how-
ever, it is possible that the increased mitogenic response results from
increased availability of energy to the cells as well as initiation of
DNA synthesis. Conversely, in the absence of insulin, glucose
supply may be rate limiting to the stimulation of mitosis by IGF-I.
Other studies have reported that the in vitro mitogenic effects of
IGF-I on human keratinocytes are similar to or greater than those
of insulin (Nickoloff et al, 1988; Neely et al, 1991; Barreca et al,
1992; Eming et al, 1996). In those experiments, other growth
factors were included in the culture media and higher human
keratinocyte densities were used to perform the growth assays. The
results reported here agree well with a study by Krane et al (1991)
where EGF was necessary to measure a positive mitogen response
to IGF-I by human keratinocytes. Both of these investigations were
performed in basal culture conditions containing only hydrocorti-
sone. Under the more stringent conditions of the clonal growth
assay, IGF-I substituted only partially for insulin in the stimulation
of human keratinocyte growth.
Neither the endogenous IGF-I produced by CSS nor the
addition of IGF-I to the CSS culture medium was adequate to
replace the insulin requirements for optimal CSS anatomy and
sustained cellular proliferation (Figs 3, 4). Light microscopy and
MTT measurements revealed that the CSS incubated in the higher
IGF-I concentration were similar to the insulin treated CSS at day
14. By day 28 signi®cant anatomic deterioration was observed in
CSS incubated only in IGF-I, and this was indistinguishable from
the negative control CSS incubated in the absence of both insulin
and IGF-I. These results support the hypothesis that insulin cannot
be replaced by IGF-I in the physiologic development of CSS.
BrdU incorporation of the CSS showed that by day 28 the 5 mg per
ml insulin treated CSS had signi®cantly higher BrdU labeling than
all other treatment groups (Fig 5). The CSS condition with 0.5 mg
per ml insulin had signi®cantly fewer BrdU-positive human
keratinocytes than the CSS with 5 mg per ml insulin, which
demonstrated that epidermal proliferation slowed signi®cantly by
day 28. This result was consistent with the light microscopy, but
not with data from the MTT assay with CSS in low dose insulin.
These data support an absolute requirement for insulin to generate
CSS with sustained mitochondrial metabolism and DNA synthesis
(Figs 4, 5). The data also suggest, however, that a lower
concentration of insulin (0.5 mg per ml) is suf®cient to maintain
mitochondrial metabolism (Fig 4), but that a higher concentration
of insulin (5 mg per ml) is required to stimulate mitosis for extended
periods of time (Fig 5). Higher insulin requirements for mitosis
may correspond to higher energy requirements for cell division
compared to G0/G1 interphase metabolism.
Epidermal barrier by measuring CSS SEC was less well
developed in the negative control lacking both insulin and IGF-I
(Fig 6). Insuf®cient supplies of glucose for lipid synthesis also
account for poor formation of epidermal barrier by CSS incubated
in medium without insulin (Fig 6). No statistical difference was
noted between the other treatment groups. The SEC data were not
supported by the CSS light microscopy and MTT data (Figs 3, 4)
inasmuch as IGF-I supplemented media resulted in poor CSS
morphology but had low surface hydration as measured by SEC. It
is probable, however, that the keratinocytes incubated in IGF-I
produced stratum corneum early in CSS development from residual
insulin carried from the proliferating human keratinocytes used to
prepare the skin substitutes. As culture time progressed, the
epidermal cells deteriorated in the media lacking insulin although
the stratum corneum remained intact in the absence of proliferating
human keratinocytes beneath. Therefore, SEC data must be
interpreted as only a measure of surface hydration that indicates
the formation of epidermal barrier but does not indicate the
proliferative capacity of keratinocytes at the time that the surface
hydration is measured. Because keratinocyte proliferation is
required for barrier formation, proliferation is the critical factor
Figure 6. Epidermal barrier forms in CSS incubated in insulin or
IGF-I. Surface electrical capacitance (pF) in CSS decreases to values not
different from native human skin (NHS) (- - - -) from 14 to 28 d of
incubation in 5 mg per ml (m) or 0.5 mg per ml (.) insulin, or 10 ng
per ml (,) or 50 ng per ml (n) IGF-I. Incubation of CSS in 0 mg per
ml insulin and 0 ng per ml IGF-I generated CSS with statistically wetter
surfaces than other groups, or than NHS (*p<0.05).
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for stable wound healing. With this consideration, SEC data should
be combined with an assessment of cellular proliferation to estimate
the ef®cacy of wound healing. It may be expected that CSS with
both proliferating keratinocytes and epidermal barrier would
provide greater ef®cacy of wound healing than proliferating
keratinocytes without barrier, and that functional stratum corneum
without proliferating keratinocytes would not heal a wound.
Insulin and IGF-I can bind to each other's receptors implying
that these factors may have overlapping functions. Experiments by
Eming et al (1996) showed that human keratinocytes genetically
modi®ed to overexpress IGF-I did not require insulin for
proliferation. This result may be attributed, in part, to the
extremely high levels of IGF-I secreted by the modi®ed cells and
a shorter assay period than reported here. Those investigators also
grafted the epithelial sheets from IGF-I modi®ed and unmodi®ed
human keratinocytes onto athymic mice with comparable in vivo
morphology. In vitro, IGF-I has been reported to be more potent
than insulin in stimulating human keratinocyte proliferation (Neely
et al, 1991). IGF-I is the only other factor with hypoglycemic
effects similar to insulin, yet IGF-I and insulin have very distinct
physiologic functions (LeRoith et al, 1994; Sherwin et al, 1994).
The studies presented here demonstrate that CSS synthesize IGF-I
in vitro although the endogenous production of IGF-I was not
adequate to support CSS development in the absence of insulin.
Also, the addition of IGF-I to the culture medium could not
reproduce the insulin-dependent CSS morphology. These experi-
ments support very strongly the hypothesis that the growth and
maturation of CSS requires insulin. It is expected that greater
homology of CSS with the anatomy and physiology of healthy
human skin will lead to reductions in mortality and morbidity from
full-thickness cutaneous wounds.
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